Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update
Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the available treatment options for patients with extrahepatic spread and vascular invasion and improved survival in patients with ad...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-11-01
|
| Series: | Liver Cancer |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/511001 |